Nadia Magdalinou

3.0k total citations · 1 hit paper
22 papers, 1.7k citations indexed

About

Nadia Magdalinou is a scholar working on Neurology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Nadia Magdalinou has authored 22 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Neurology, 10 papers in Physiology and 8 papers in Psychiatry and Mental health. Recurrent topics in Nadia Magdalinou's work include Parkinson's Disease Mechanisms and Treatments (13 papers), Alzheimer's disease research and treatments (10 papers) and Dementia and Cognitive Impairment Research (8 papers). Nadia Magdalinou is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (13 papers), Alzheimer's disease research and treatments (10 papers) and Dementia and Cognitive Impairment Research (8 papers). Nadia Magdalinou collaborates with scholars based in United Kingdom, Sweden and United States. Nadia Magdalinou's co-authors include Henrik Zetterberg, Kaj Blennow, Jonathan M. Schott, Andrew J. Lees, Ross W. Paterson, Nick C. Fox, Amanda Heslegrave, Ulf Andréasson, Wendy Heywood and Radu Constantinescu and has published in prestigious journals such as Neurology, Annals of the New York Academy of Sciences and Journal of Neurochemistry.

In The Last Decade

Nadia Magdalinou

21 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blood-based NfL

2017 356 citations Oskar Hansson, Shorena Janelidze et al. Neurology profile →

Peers

Countries citing papers authored by Nadia Magdalinou

Since Specialization

Citations

This map shows the geographic impact of Nadia Magdalinou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Magdalinou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Magdalinou more than expected).

Fields of papers citing papers by Nadia Magdalinou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Magdalinou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Magdalinou. The network helps show where Nadia Magdalinou may publish in the future.

Co-authorship network of co-authors of Nadia Magdalinou

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Magdalinou. A scholar is included among the top collaborators of Nadia Magdalinou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Magdalinou. Nadia Magdalinou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease 2019 ·PubMed ·(unknown), Rahil Dahlén, Oskar Hansson, (unknown), Ross W. Paterson, Jonathan M. Schott, Nadia Magdalinou, Henrik Zetterberg, Kaj Blennow, Johan Gobom	6
2	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes 2019 ·Journal of Neurology Neurosurgery & Psychiatry ·Edwin Jabbari, John Woodside, Tong Guo, Nadia Magdalinou, Viorica Chelban, Dilan Athauda, Andrew J. Lees, Thomas Foltynie, Henry Houlden, Alistair Church, (unknown), James B. Rowe, Henrik Zetterberg, Huw R. Morris	39
3	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease 2018 ·Annals of Clinical and Translational Neurology ·Henrietta Wellington, Ross W. Paterson, Aida Suárez‐González, Teresa Poole, Chris Frost, Ulrika Sjöbom, Catherine F. Slattery, Nadia Magdalinou, Manja Lehmann, (unknown), Nick C. Fox, Kaj Blennow, Henrik Zetterberg, Jonathan M. Schott	28
4	Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic 2018 ·Alzheimer s Research & Therapy ·Ross W. Paterson, Catherine F. Slattery, Teresa Poole, Jennifer M. Nicholas, Nadia Magdalinou, Jamie Toombs, Miles Chapman, Michael P. Lunn, Amanda Heslegrave, Martha Foiani, Philip S.J. Weston, Ashvini Keshavan, Jonathan D. Rohrer, Martin N. Rossor, Jason D. Warren, Catherine J. Mummery, Kaj Blennow, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott	105
5	Blood-based NfL breakdown → 2017 ·Neurology ·Oskar Hansson, Shorena Janelidze, Sara Hall, Nadia Magdalinou, Andrew J. Lees, Ulf Andréasson, Niklas Norgren, Jan Linder, Lars Forsgren, Radu Constantinescu, Henrik Zetterberg, Kaj Blennow, (unknown)	356
6	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics 2017 ·Parkinsonism & Related Disorders ·Nadia Magdalinou, Alastair J. Noyce, Rui Pinto, (unknown), Jessica Holmén‐Larsson, Mikko Hölttä, Kaj Blennow, Huw R. Morris, Tobias Skillbäck, Thomas T. Warner, Andrew J. Lees, Ian Pike, Malcolm Ward, Henrik Zetterberg, Johan Gobom	35
7	[O4–02–01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON's AND ALZHEIMER's DISEASE 2017 ·Alzheimer s & Dementia ·Edwin Jabbari, John Woodside, Nadia Magdalinou, Kaj Blennow, Henrik Zetterberg, Andrew J. Lees, Huw R. Morris	0
8	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer’s disease pathology 2016 ·Translational Psychiatry ·Ross W. Paterson, Wendy Heywood, Amanda Heslegrave, Nadia Magdalinou, Ulf Andréasson, Ernestas Sirka, (unknown), Catherine F. Slattery, Jamie Toombs, Johan Svensson, Per Johansson, Nick C. Fox, Henrik Zetterberg, Kevin Mills, Jonathan M. Schott	51
9	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease 2016 ·Molecular Neurodegeneration ·Amanda Heslegrave, Wendy Heywood, Ross W. Paterson, Nadia Magdalinou, Johan Svensson, Per Johansson, Annika Öhrfelt, Kaj Blennow, John Hardy, Jonathan M. Schott, Kevin Mills, Henrik Zetterberg	237
10	O1‐11‐05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic 2016 ·Alzheimer s & Dementia ·Ross W. Paterson, Catherine F. Slattery, Nadia Magdalinou, Jamie Toombs, Miles Chapman, Michael P. Lunn, Kaj Blennow, Nick C. Fox, Henrik Zetterberg, (unknown)	1
11	Increased CSF neurogranin concentration is specific to Alzheimer disease 2016 ·Neurology ·Henrietta Wellington, Ross W. Paterson, Erik Portelius, Ulrika Törnqvist, Nadia Magdalinou, Nick C. Fox, Kaj Blennow, Jonathan M. Schott, Henrik Zetterberg	179
12	Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids 2016 ·ACS Chemical Neuroscience ·Mathew H. Horrocks, Steven F. Lee, Sonia Gandhi, Nadia Magdalinou, Serene W. Chen, Michael J. Devine, Laura Tosatto, Magnus Kjærgaard, Joseph S. Beckwith, Henrik Zetterberg, Marija Iljina, Nunilo Cremades, Christopher M. Dobson, Nicholas Wood, David Klenerman	93
13	P1‐010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker? 2015 ·Alzheimer s & Dementia ·Henrietta Wellington, Ulrika Törnqvist, Erik Portelius, Ross W. Paterson, Nadia Magdalinou, Nick C. Fox, Kaj Blennow, Jonathan M. Schott, Henrik Zetterberg	2
14	Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis 2015 ·Journal of Neurology ·Ross W. Paterson, Jamie Toombs, Catherine F. Slattery, Jennifer M. Nicholas, Ulf Andréasson, Nadia Magdalinou, Kaj Blennow, Jason D. Warren, Cath Mummery, Martin N. Rossor, Michael P. Lunn, Sebastian J. Crutch, Nick C. Fox, Henrik Zetterberg, Jonathan M. Schott	41
15	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay 2015 ·Molecular Neurodegeneration ·Wendy Heywood, Daniela Galimberti, (unknown), Ernestas Sirka, Ross W. Paterson, Nadia Magdalinou, Miryam Carecchio, Emma Reid, Amanda Heslegrave, Chiara Fenoglio, Elio Scarpini, Jonathan M. Schott, Nick C. Fox, John Hardy, (unknown), Simon Heales, Neil J. Sebire, (unknown), Kevin Mills	124
16	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes 2015 ·Journal of Neurology Neurosurgery & Psychiatry ·Nadia Magdalinou, Ross W. Paterson, Jonathan M. Schott, Nick C. Fox, Catherine J. Mummery, Kaj Blennow, Kailash P. Bhatia, Huw R. Morris, Paola Giunti, Thomas T. Warner, (unknown), Andrew J. Lees, Henrik Zetterberg	194
17	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions 2014 ·Journal of Neurology Neurosurgery & Psychiatry ·Nadia Magdalinou, Andrew J. Lees, Henrik Zetterberg	75
18	Perceptual decision-making in patients with Parkinson’s disease 2014 ·Journal of Psychopharmacology ·Atbin Djamshidian, Sean S. O’Sullivan, Andrew D. Lawrence, Thomas Foltynie, Icíar Avilés-Olmos, Nadia Magdalinou, Alessandro Tomassini, Thomas T. Warner, Andrew J. Lees, Bruno B. Averbeck	20
19	Development and assessment of sensitive immuno‐PCR assays for the quantification of cerebrospinal fluid three‐ and four‐repeat tau isoforms in tauopathies 2012 ·Journal of Neurochemistry ·(unknown), Yaroslau Compta, Nadia Magdalinou, Marı́a José Martı́, Geshanthi Hondhamuni, Henrik Zetterberg, Kaj Blennow, Radu Constantinescu, Yolande A.L. Pijnenburg, Brit Mollenhauer, Claudia Trenkwalder, John C. van Swieten, (unknown), Barbara Borroni, Ana Cámara, (unknown), David R. Williams, Andrew J. Lees, Rohan de Silva	46
20	Normal pressure hydrocephalus or progressive supranuclear palsy? A clinicopathological case series 2012 ·Journal of Neurology ·Nadia Magdalinou, Helen Ling, James D. Smith, Jonathan M. Schott, Laurence Watkins, (unknown)	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact